Trial Radar
Sign in

Study record

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470

RecruitingPhase 4

Sponsor: Alpha Cognition, Inc

Conditions: Alzheimer Disease

Interventions: Zunveyl®

Countries: United States

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

1 events · 1 snapshots

1 recorded events1 registry snapshotsTracked since Sep 1, 2026Official CT.gov history
  1. Sep 1, 2026
    New TrialNotable

    Alpha Cognition, Inc started Phase 4 Alzheimer Disease trial

    Registry state after update: Recruiting · Phase 4 · 1 countries

← Back to dashboard